A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
This study aims to characterize the profile and outcomes for patients with Squamous Cell Carcinoma of the Lung (SqCC) who progress on 1L pembrolizumab in combination with platinum based chemotherapy and receive afatinib as second line (2L) therapy.
Checked against the public recordLast updated Jan 11, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Boehringer Ingelheim
- Interventions being studied
- Drug: Second line (2L) afatinib; Drug: Second line chemotherapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Diagnosis of squamous or mixed histology non-small cell lung cancer * Treated with pembrolizumab in combination with platinum-based chemotherapy as initial therapy for advanced or metastatic disease (stage IIIB or IV) * First cycle of pembrolizumab received after 06/01/2018 * Permanently discontinued 1L pembrolizumab treatment * Initiated second-line treatment at least 3 months prior to the date of data collection, with either : * Afatinib * Any chemotherapy * Age ≥ 18 years Exclusion Criteria: -Received pembrolizumab in combination with platinum-based chemotherapy as part of an interventional clinical trial
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cardinal Health Specialty SolutionsDublin, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 11, 2022. Always confirm current availability with the study team.